Scholarlink

Background <p>Translating trial findings to real-world cure rates for resectable oesophageal and gastroesophageal junction (GEJ) adenocarcinoma is critical. Standard endpoints like disease-free survival (DFS) may not distinguish durable cures from delayed recurrences.</p> Methods <p>This analysis of the AGAMENON-SEOM registry (NCT04958720) compared perioperative chemotherapy versus neoadjuvant chemoradiotherapy (nCRT). We estimated cure rates and analysed DFS and overall survival (OS) using mixture cure models and Cox proportional hazards models.</p> Results <p>In 500 patients, perioperative FLOT improved DFS (HR 0.60; <i>p</i> = 0.01) and OS (adjusted HR 0.63; <i>p</i> = 0.015) compared to CROSS-based nCRT. Notably, cure models confirmed a higher cure fraction for FLOT in high-risk subgroups (e.g., stage III, high neutrophil-to-lymphocyte ratio). While platinum-fluoropyrimidine–based nCRT ± immunotherapy yielded higher R0 and pathological complete response rates, its estimated cure rate was comparable to FLOT, both overall and across all subgroups.</p> Conclusion <p>Cure is an informative endpoint in localised oesophageal cancer. In this registry analysis, perioperative FLOT was associated with higher cure rates than CROSS, particularly in high-risk subgroups. Exploratory findings suggest that alternative neoadjuvant strategies, such as those incorporating ICIs or FOLFOX, warrant further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Lucía Mateos,
  • Paula Jiménez-Fonseca,
  • Javier Gallego,
  • Arturo Lecumberri,
  • Ana Custodio,
  • Eva Martínez de Castro,
  • Raquel Hernández San Gil,
  • Ana Fernández Montes,
  • María Luisa Limón,
  • Rosario Vidal-Tocino,
  • Juana María Cano,
  • Javier López Robles,
  • Mireia Gil,
  • Daniel Acosta Eyzaguirre,
  • Gema Marín Zafra,
  • Antonio José Mérida-García,
  • Alejandro Francisco Fernández,
  • Paula Ribera Fernández,
  • Cinta Hierro,
  • María Carmen Riesco,
  • Montse García Araque,
  • Maribel Ruiz Martín,
  • Paola Pimentel,
  • Laura Visa,
  • Paula Cerdá,
  • Mónica Granja,
  • Ana Belén Rupérez Blanco,
  • Lourdes Gutiérrez,
  • Alberto Carmona-Bayonas

摘要

Background

Translating trial findings to real-world cure rates for resectable oesophageal and gastroesophageal junction (GEJ) adenocarcinoma is critical. Standard endpoints like disease-free survival (DFS) may not distinguish durable cures from delayed recurrences.

Methods

This analysis of the AGAMENON-SEOM registry (NCT04958720) compared perioperative chemotherapy versus neoadjuvant chemoradiotherapy (nCRT). We estimated cure rates and analysed DFS and overall survival (OS) using mixture cure models and Cox proportional hazards models.

Results

In 500 patients, perioperative FLOT improved DFS (HR 0.60; p = 0.01) and OS (adjusted HR 0.63; p = 0.015) compared to CROSS-based nCRT. Notably, cure models confirmed a higher cure fraction for FLOT in high-risk subgroups (e.g., stage III, high neutrophil-to-lymphocyte ratio). While platinum-fluoropyrimidine–based nCRT ± immunotherapy yielded higher R0 and pathological complete response rates, its estimated cure rate was comparable to FLOT, both overall and across all subgroups.

Conclusion

Cure is an informative endpoint in localised oesophageal cancer. In this registry analysis, perioperative FLOT was associated with higher cure rates than CROSS, particularly in high-risk subgroups. Exploratory findings suggest that alternative neoadjuvant strategies, such as those incorporating ICIs or FOLFOX, warrant further investigation.